European Pharmaceutical Pricing And Reimbursement


Published on

This exciting conference will provide attendees with a complete view of the pricing and market access fields.

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

European Pharmaceutical Pricing And Reimbursement

  1. 1. European Pharmaceutical Pricing & Reimbursement SMi present their 18th annual conference on… 29th-30th October 2012, Copthorne Tara Hotel, London, UKREGISTER BY 20TH JULY AND RECEIVE A £300 DISCOUNT KEY SPEAKERS INCLUDE: Pierrick Rollet Anant Murthy VP, Global Market Access, Senior Director, Pricing and Market GlaxoSmithKline Access, EMEA, Celgene Uday Bose EMEA, Oncology Business Unit Laura Crippa Head, Strategic Operations Director, Eisai Temas s.r.l. Toros Sahin Tomas Dolezal Market Access Manager, Director, Sanofi IHETA Michael Wang Janie Haigh VP, Global Market Access, Grunenthal Practice Leader, Market Access Europe, Quintiles Thilo Schaufler Head of Market Access & Timothy Lenehan, Governmental Affairs, Market Access Director, Abbott UCB Pharma KEY REASONS TO ATTEND: • Hear from experts in the field on Value Based Pricing: Principles and practice PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS • Debate EU policy challenges in access to medicines in Europe • Analyse market access in Russia, Turkey and Eastern Europe • Learn about the latest regulations within pricing and reimbursement from • Understand the facts and consequences of Germany’s AMNOG • Discover the value of collaboration in HTA and managed entry schemes A: Developing International Price Referencing systems B: The potential impact of the German AMNOG on the European Pricing & Reimbursement environment Wednesday 31st October 2012, Copthorne Tara Hotel, London Workshop Leaders: Gary Johnson, Managing Director and Nick Taylor, Senior Business Analyst and IPR Expert, Workshop Leader: Stefan Walzer, General Manager, MArS Inpharmation Market Access & Pricing Strategy UG 9.00am – 12.30pm 1.30pm-5.00pmRegister online and receive full information on all of SMi’s conferencesAlternatively fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711 Sponsored by
  2. 2. European Pharmaceutical Pricing & Reimbursement 2012 Day One Monday 29th October 2012 www.pharmaceu 8.30 Registration & Coffee 12.20 Networking Lunch 9.00 Chairman’s Opening Remarks PRICING AND MARKET ACCESS SYSTEMS ACROSS EUROPE Neil Palmer, President and Principal Consultant, PDCI Market Access 1.40 Market Access Strategies in Italy CURRENT DEVELOPMENTS IN THE FIELD •  National phase: new commissions, old commitments? •  Recognising and rewarding innovation: the updated algorhythm 9.10 Evolution of pricing and reimbursement strategies in oncology •  Raising awareness in a regulated country • Review the payer and pharma perspective with respect to pricing •  The approach to Regions and reimbursement • Examine key evolutions in how payers have been assessing Laura Crippa, Director, Market Access and Pricing, Temas Srl oncology products • Review and critique of case studies 2.20 Pricing and reimbursement system in Turkey • Describe potential changes moving forward and steps Pharma • Healthcare Landscape and Latest Developments – where is Turkey should consider to prepare compared to EU? Uday Bose, EMEA, Oncology Business Unit Head, Eisai Europe Ltd • Pricing System – how did the reforms had an impact on pricing? • Reimbursement System – how is the system working and what are 9.50 Can talking to payers (or ex-payers) do more harm than good? the obstacles? • The ritual of talking to a small number of ex-payers, advisers to • Expectations for the future payers etc. to investigate how a novel pharmaceutical could be Toros Sahin, Market Access Manager, Sanofi priced is well established.  But does it work? • Do payers “game” and deliberately mislead? • Do payers all think the same way?  And if not, does talking to a 3.00 Survival: The first 2 years of AMNOG very small number of people introduce huge sampling error? • AMNOG process: Put into stone? Political update • Does what payers say relate to what they actually do?  And, if not, • AMNOG learning from history: Which were the mistakes you should could we just analyse their behaviour? avoid? Gary Johnson, Managing Director, Inpharmation • Survived! Key tactics for a successful GBA submission and price negotiation 10.30 Morning Coffee Stefan Walzer, General Manager, MArS Market Access & Pricing Strategy UG 11.00 Trends in HTA – What is happening where? Register online at• Alternatively fa • An analysis from Quintiles HTA Watch comparing actual 3.40 Afternoon Tea assessments and decisions from leading HTA agencies • Update on GB-A and IQWiG decisions – how do these compare with other HTA agencies? 4.00 The Role of the HTA; A Central European Perspective • Use of PROs – to what extent can these influence decisions? • Recent developments in the region: HTA on the way Janice Haigh, Practice Leader, Market Access Europe, Quintiles • New legislative and regulatory challenges for pharmaceuticals • Market access strategies tailored for CEE markets 11.40 Implementing HTA in Switzerland - A Multi-Stakeholder Approach • How to escape from price reference trap? • The Euro-crisis exposed weaknesses of Swiss reimbursement • Different approaches to orphan drugs and innovative treatments system, emphasizing need for a more value-based approach Tomas Dolezal, Director, IHETA • Under the current system, there is little incentive to register new products or additional indications for reimbursement 4.40 The impact of Value Based Pricing in the UK • Pharmaceutical industry, health insurances, physician organisation • VBP – What will it look like? collaborated to present a joint reform proposal to the Swiss government • Challenges for the industry • The implementation of formalized HTA in Switzerland will present • Impact on innovation further challenges to all stakeholders Leslie Galloway, Chairman, Ethical Medicines Industry Group Thilo Schaufler, Head of Market Access and Governmental Affairs, Abbott 5.20 Chairman’s Closing Remarks and Close of Day One Sponsored by Inpharmation specialises in evidence based market modelling for the pharma industry. All the top 10 global pharma companies are clients. Inpharmation allows clients to model pricing strategy, international pricing (parellel trade, reference pricing etc.), future sales (forecasting), promotional response and marketing mix, risk, R&D portfolio. All modelling projects are ‘evidence based’ and are backed up by rigorous research and validation. Inpharmation’s key capabilities are a strategic understanding of the pharma industry, a detailed knowledge of modelling techniques and advanced programming skills. PDCI Market Access (PDCI) is a leading pharmaceutical pricing and reimbursement (P&R) consultancy based in Ottawa and Toronto. Established in 1996, the firm features a senior team of multilingual market access professionals with extensive experience assisting clients through the challenging market access environment facing pharmaceutical and medical device manufacturers in Canada. PDCI develops successful P&R strategies and prepares comprehensive submissions to CDR, pCODR, public & private payers and the PMPRB. The firm’s senior consultants facilitate meetings with CDR/payers/PMPRB, negotiate product listing agreements (PLAs) and resolve pricing compliance issues with the PMPRB. As part of its C-MAP research and subscriptions services, PDCI maintains databases of international pharmaceutical prices, provincial drug claims and costs and is the publisher of the comprehensive Canadian Drug Benefit Plan (CDBP) reference guide that assists subscribers navigate the complex submission requirements of HTA agencies and reimbursement authorities in Canada. www.pdci.caSupported by
  3. 3. European Pharmaceutical Pricing & Reimbursement Day Two Tuesday 30th October 2012 8.30 Re-registration & Coffee 12.20 Networking Lunch 9.00 Chairmans Opening Remarks 1.30 Latest changes to P&R in Japan Gary Johnson, Managing Director, Inpharmation • Launch price setting • Price revision MARKET ACCESS FOR ORPHAN DRUGS • Premium for new drug development • Promotion of generic use • Prospects for Health Technology Assessments 9.10 Value and patient access considerations: a possible framework Donald Macarthur, Global Pharmaceutical Business Analyst, for Improving access to rare diseases treatments JustPharmaReports • Rare Diseases environment - key facts & features • Rare diseases treatments – drivers & challenges for improved 2.10 Panel Discussion: Market Access Developments: patient access Europe vs Rest of the World • Value & patient access considerations for rare diseases • How can markets adapt to the changes in payer needs treatments: which possible framework for improved patient • Methods of flexible financial arrangements access? Options, issues and future directions • What can these markets learn from each other Pierrick Rollet, VP, Global Market Access, GlaxoSmithKline Chair: Gary Johnson, Managing Director, Inpharmation Neil Palmer, President and Principal Consultant, PDCI Market 9.50 Developments in Orphan Drugs Market Access Access Timothy Lenehan, Market Access Director, UCB Pharma • EU rules and market access scenario of Orphan Drugs • The Italian market access fast track 2.40 Afternoon Tea • Premium price • Research and development incentives and reward PRICING UPDATES AND REFORMS Fabrizio Gianfrate, Professor of Health Economics, University of Ferrara 3.00 Distant Cries: Designing clinical trial needs today for tomorrow’s access and pricing 10.30 Morning Coffee • The importance of effective clinical trial design for pricing • Advantages in terms of market access WORLDWIDE DEVELOPMENTS IN MARKET ACCESS • Short term effects and long term developments Michael Wang, VP, Global Market Access, Grunenthal 11.00 Canadian Market Access Overview Cyrus Chowdhury, Managing Director, CB Partnersax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711 • Overview of Canadian health care system and pharmaceutical 3.40 Risk-Sharing: Developing a commercial strategy funding • How should manufacturers define opportunities for innovating • Price regulation: impact of the new PMPRB guidelines pricing? • CADTH/CDR, pCODR, provincial reimbursement schemes & • Orphan Drugs: How are they different? listing (risk sharing) agreements • How to weigh challenges and opportunities • National implications of the Ontario 20% pricing rule for • Innovating pricing in the context of EU P&R reforms generics Anant Murthy, Senior Director, Pricing & Market Access, EMEA, • Implications of international pricing/reimbursement policy Celgene reforms (AMNOG, VBP) on Canada • Outlook for Canadian pricing & reimbursement 4.20 Effects of the proposed reform of the EU Transparency Directive Neil Palmer, President and Principal Consultant, PDCI Market • Overview of issues arising under the current Transparency Access Inc. Directive • Proposal to amend the Transparency Directive, including: - shorter periods for Member States to take decisions 11.40 Update on Healthcare Reform in the Russian Federation - taking account of HTA procedures • Evolution of Reform SMis Pharmaceutical Forward Planner 2012 - monitoring and sanctioning non-compliance • Current Status • Prognosis for when the proposal might be adopted • What’s Expected James Killick, Partner, White & Case L L P • What does this mean for Pharma Companies? Timothy Lenehan, Market Access Director, UCB Pharma 5.00 Chairmans Closing Remarks and Close of Day Two SPONSORSHIP OPPORTUNITIES Our pharmaceutical events are research-based and content-driven with regular contact with major industry personnel and cover a wide range of industry sectors. For more information, please contact Alia Malick on +44 (0) 207 827 6168 or email JULY OCTOBER NOVEMBER 2-3 KOL Management and MSL Best 3-4 Partnerships with CROs 5-6 Cell Based Assays Practice in Europe (Switzerland) 8-9 Pharmaceutical Orphan 5-6 Clinical Trials in CNS 9-10 ADMET Drugs 28-29 Diabetes Want to know how you can get involved? Interested in 9-10 Social Media in the 22-23 COPD: Novel promoting your pharmaceutical services to this Pharmaceutical Industry Therapeuticsand DECEMBER market? Contact Margaret Mugema, 11-12 BioBanking Management Strategies 3-4 Cold Chain Distribution SMi Marketing on +44 (0)20 7827 6072 or email 24-25 Point of Care Diagnostics SEPTEMBER - Market Opportunities All conferences take place in central 17-18 Next Generation Sequencing and Technology Trends London, UK 19-20 Cancer Vaccines 29-30 European Pharmaceutical Pricing 24-25 Biosimilars and Biobetters & Reimbursement 26-27 KOL Management
  4. 4. A: Developing International Price Referencing systems HALF-DAY POST-CONFERENCE AM WORKSHOP Wednesday 31st October 2012 9.00am – 12.30pm Copthorne Tara Hotel, LondonOverview of workshop In association withThe workshop will show why understanding the IPRsystem is so important in todays economic climate.Attendees will learn that IPR is a system – a small changein one part has knock-on effects throughout the system.The right price in one country and an optimal launch ordercan have huge effects on revenues. Modeling systems canbe complicated especially as they often behave counter-intuitively. However, trying to model everything can lead toparalyzing complexity. The key to good modelling is a goodunderstanding of the system – knowing what is important.The workshop will conclude with a real life case studydemonstrating how correct modelling of the IPR systemcan maximise revenues.Why you should attend:• Learn how best to develop and apply international price referencing• Discover the importance of correct modeling on product success• Develop techniques to improve of pricing strategies by discussing industry case studies• Evaluate the key points that must be considered when modelling this complex system• Network with key industry professionalsProgramme:8:30 Registration & coffee9:00 Welcome & introductions9:10 Why International Price Referencing is becoming ever more important9:45 Examples of the main errors when trying to model the effects of international price referencing10:45 Morning coffee break11:00 The keys to successful modelling of the international price referencing system12:10 Case study showing how correct modelling greatly enhances product revenues12:30 Close of workshopAbout the workshop host:Gary Johnson is Managing Director of Inpharmation Ltd. Hehas consulted for all the top 10 pharma companies and manyothers too. He is author of the book Principles ofPharmaceutical Pricing: An Evidence Based Approach and afinalist for the MCA Business Book of the Year Award. He hasa number of prestigious best paper awards at internationalconferences. Prior to founding Inpharmation, Gary held seniorpositions in major pharma companies. He has degrees inMedical Science from Nottingham and Management fromLondon. He is a Sloan Fellow of London Business School anda Fellow of the Royal Society of MedicineAbout InpharmationInpharmation specialises in evidence based marketmodelling for the pharma industry. All the top 10 globalpharma companies are clients. Inpharmation allows clients tomodel pricing strategy, international pricing (parallel trade,reference pricing etc.), future sales (forecasting), promotionalresponse and marketing mix, risk, R&D portfolio. Allmodelling projects are ‘evidence based’ and are backed up byrigorous research and validation. Inpharmation’s keycapabilities are a strategic understanding of the pharmaindustry, a detailed knowledge of modelling techniques andadvanced programming skills.
  5. 5. B: The potential impact of the German AMNOG on the European Pricing & Reimbursement environmentHALF-DAY POST-CONFERENCE PM WORKSHOP Wednesday 31st October 2012 1.30am – 5.00pm Copthorne Tara Hotel, LondonOverview of workshop In association withThe purpose of this workshop is to analyse the potentialimpact of the German AMNOG process on the EuropeanPricing & Reimbursement (P&R) environment. P&Rprocesses of key European countries will be analysed withrespect to a potential spill-over of the German AMNOGprocess. The impact of NICE on various European P&Rdecisions is well known. However the impact of theGerman AMNOG which focuses much more on evidencebased medicine instead of cost-effectiveness, on otherEuropean P&R negotiations is not yet known but couldhave an even greater impact on a European level. Theworkshop will introduce briefly the AMNOG process and willlay out the potential spill-over areas for other EuropeanP&R negotiations. The various European pricing &reimbursement school of thoughts will be analysed withrespect to the potential impact of the German AMNOGwhich will then also be openly discussed with the audience.Why you should attend:• Learn how best to develop pricing strategies across Europe• Consider the latest developments in the AMNOG and their effects on other national pricing systems• Understand and predict potential obstacles and discuss how best to prepare and avoid them• Network with key industry professionals• Utilize the experience of an expert in the fieldProgramme:1.30 Welcome and introduction1.40 The German AMNOG process: A brief re-cap2.00 European Pricing & Reimbursement (P&R) schools of thought and the potential link to AMNOG2.30 Interactive work in small teams supported by the workshop leader: • AMNOG impact on P&R in the three schools of thought • Potential opportunities & risks for the various stakeholders in case of more or less harmonization between4.00 Coffee break4.15 Presentation of workshop results4:45 Re-cap and closureAbout the workshop host:Dr . Walzer has more than 8 years experience in payer strategy and itsimplementation and is the founder and general manager MArS MarketAccess & Pricing Strategy UG (h.b.) based in Germany. He previouslyworked as a payer consultant for various global pharmaceutical andmedical device companies, successfully launching their products acrossthe world. Dr . Walzer was also the Global Payer Strategy Leader forvarious products and compounds of F. Hoffmann – La Roche AG, wherehe successfully developed early payer strategies as well as launchingand maintaining the eimbursement process for top oncology brandsand early compounds. Dr Walzer has been working on various projectsaround AMNOG in the last years and is well connected to variousacademic institutions in Germany and Europe. Dr . Walzer received aMaster of Science in Economics from the University of Tuebingen(Germany), a PhD in Health Economics from the University of Zurich(Switzerland) and a Diploma in Clinical Trials from the London School ofAbout MArS Market Access & Pricing Strategy:Hygiene and Tropical Medicine (UK). He is co-author of more than 25peer-reviewed scientific articles and more than 40 scientific abstracts.MArS Market Access & Pricing Strategy is a specializedconsulting agency in the health care market access area with aspecial focus and experience in the following two key areas:• Global development and market access strategies in the various lifecycle stages of a product (Phase I-Phase IV)• German market access strategies with the focus on the German Law for Reforming the Market for Pharmaceuticals (AMNOG)
  6. 6. EUROPEAN PHARMACEUTICAL PRICING & REIMBURSEMENT 4 WAYS TO REGISTER your booking form to +44 (0) 870 9090 712 POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor South,PHONE on +44 (0) 870 9090 711 CONFERENCE PRICES Conference: Monday 29th and Tuesday 30th October 2012, Copthorne Tara Hotel, London, UK Workshops: Wednesday 31st October 2012, London EARLY BIRD Harling House, 47-51 Great Suffolk Street, London, SE1 0BS DISCOUNTDELEGATE DETAILS □ Book by 20th July to receive £300 off the conference price I would like to attend: (Please tick as appropriate) Fee Total □ Conference & 2 Workshops £2697.00 + VAT £3236.40 □ Conference & 1 Workshop £2098.00 + VAT £2517.60 □ Conference only £1499.00 + VAT £1798.80 □ 1 Workshop only £599.00 + VAT £718.80 VENUE □ 2 Workshops only £1198.00 + VAT £1437.60Unique Reference Number Workshop A □ Workshop B □Our Reference P-050 DOCUMENTATION PROMOTIONAL LITERATURE DISTRIBUTION GROUP DISCOUNTS AVAILABLE □ Distribution of your company’s promotional literature to all conference attendees £999.00 + VAT £1198.80Title: Forename:Surname: The Conference fee includes refreshments, lunch, conference papers andJob Title: CD ROM containing all of the presentations.Department/Division: □ Please contact me to book my hotelCompany/Organisation:Please complete fully and clearly in capital letters. Please photocopy for additional delegates. Copthorne Tara Hotel, Scarsdale Place, Kensington, London, W8 5SREmail: PAYMENTAddress: Alternatively call us on +44 (0) 870 9090 711, email: or fax +44 (0) 870 9090 712Town/City:Post/Zip Code: Country: (Shipped 10-14 days after the event)Direct Tel: Direct Fax: I cannot attend but would like to purchase access to the following Document Portal/paper copy documentation: Price TotalMobile: □ Access to the conference documentation on the Document Portal £499.00 + VAT £598.80Switchboard:Terms and Conditions of Booking □ The Conference Presentations - paper copy £499.00 - £499.00Signature: Date:ACCOUNTS DEPTTitle: Forename: (or only £300 if ordered with the Document Portal)Surname:Email: Payment must be made to SMi Group Ltd, and received before the event, by one of theI agree to be bound by SMis Terms and Conditions of Booking.Address (if different from above): following methods quoting reference P-050 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment: Valid From □□/□□ Expiry Date □□/□□Town/City: □ UK BACS Sort Code 300009, Account 00936418Post/Zip Code: Country: □ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418Direct Tel: Direct Fax: IBAN GB48 LOYD 3000 0900 9364 18 VAT □ Cheque We can only accept Sterling cheques drawn on a UK bank. □ Credit Card □ Visa □ MasterCard □ American Express Card No: All credit card payments will be subject to standard credit card charges. CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card Cardholder’s Name:Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid Signature: Date:immediately and prior to the start of the event. If payment has not been received then credit card details willbe requested and payment taken before entry to the event. Bookings within 7 days of event require paymenton booking. Access to the Document Portal will not be given until payment has been received. Card Billing Address (If different from above):Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate totake your place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place atan event. Please make separate bookings for each delegate.Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, thenwe will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is madein writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this timecannot be accepted. We will however provide the conferences documentation via the Document Portal to anydelegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings I agree to be bound by SMis Terms and Conditions of Booking.we are not normally able to provide documentation in these circumstances. We cannot accept cancellations VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on CDof orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at ROMs and Literature Distribution for all UK customers and for those EU customers notwe have to cancel the event for any reason, then we will make a full refund immediately, but disclaim anyfurther liability. supplying a registration number for their own country here: _______________________Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue ordate of the event compared to the advertised programme.Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998and we may use this to contact you by telephone, fax, post or email to tell you about other products andservices. Unless you tick here □ we may also share your data with third parties offering complementaryproducts or services. If you have any queries or want to update any of the data that we hold then pleasecontact our Database Manager or visit our quoting the URN as detailed above your address on the attached letter. □□□□ □□□□ □□□□ □□□□